SCHEMBL1711050

SCHEMBL1711050

Nc1ccc(C(=O)N2CCN(c3ccccc3)CC2)cc1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.74
KMT2A Q03164 4/20 0.74
POLB P06746 2/20 0.74
SLC6A7 Q99884 2/20 0.74
CA12 O43570 1/20 0.69
CA1 P00915 1/20 0.69
CA2 P00918 1/20 0.69
CA7 P43166 1/20 0.69
CA9 Q16790 1/20 0.69
CA14 Q9ULX7 1/20 0.69
TSHR P16473 4/20 0.67
LMNA P02545 4/20 0.67
USP2 O75604 2/20 0.67
MAPT P10636 1/20 0.67
MAPK1 P28482 1/20 0.67
HSD17B10 Q99714 1/20 0.65
ALDH1A1 P00352 3/20 0.63
DRD2 P14416 1/20 0.62
HTR2A P28223 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19562172 0.94 MEN1 (0.67) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL24641653 0.94 LMNA (0.72) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL10721777 0.92 MEN1 (0.87) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL8595777 0.88 POLB (0.87) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL3276407 0.87 MEN1 (0.74) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL27861127 0.86 TSHR (0.69) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL8161635 0.85 SLC6A7 (1.00) MEN1KMT2APOLBSLC6A7CA12
SCHEMBL9321490 0.84 LMNA (0.74) POLBCA12CA1CA2CA7
SCHEMBL21526333 0.84 HSP90AA1 (0.74) MEN1KMT2ASLC6A7CA12CA1
SCHEMBL6791126 0.84 SMN1; SMN2 (0.67) MEN1KMT2APOLBSLC6A7CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 MEN1 824/4885KMT2A 777/4885POLB 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.